Press Releases

• Akero Therapeutics: Presents New Analyses From Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting 2025 More
• A2 Biotherapeutics: Presents Initial Safety and Efficacy Data From Ongoing Phase 1/2 EVEREST-2 Study, Including First Report of a Complete Response to CAR T-Cell Therapy in a Patient With NSCLC More
• Aulos Bioscience: New Phase 2 Data for Imneskibart Reveal Clinical Activity in Melanoma and Non-Small Cell Lung Cancer More
• Coherus Oncology: Arvind Sood Joins As Chief Strategy and Corporate Affairs Officer More
• Denali Therapeutics: Board and Executive Leadership Updates More More* More*
  
• Gilead: Livdelzi Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression More
• Gilead: Update on Phase 3 ASCENT-07 Study More
• Nurix Therapeutics: Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling More
• ORIC Pharmaceuticals: Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor More
• Synthekine: Presents Positive Initial Results from Phase 1a/1b Clinical Trial of STK-012 Plus Pembrolizumab and Chemotherapy in First-Line, PD-L1 Negative Nonsquamous Non-Small Cell Lung Cancer More
• Tahoe Therapeutics: Welcomes Proven Discovery Leaders Wayne Spevak, Ph.D., and Ben Powell, Ph.D., to Advance Drug Discovery More
• UroViu: Receives CE Certification of Its Wi-Fi Enabled Cystoscope and Hysteroscope Product Portfolio More
• Vera Therapeutics: Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine More
• 8 More*

Financial News

• Aligos Therapeutics: Recent Business Progress and Third Quarter 2025 Financial Results More
• Allogene Therapeutics: Third Quarter 2025 Financial Results and Business Update More
• Cerus: Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance More
• Codexis: Third Quarter 2025 Financial Results More
• Coherus Oncology: Third Quarter 2025 Financial Results and Provides Business Update More
• CytomX Therapeutics: Third Quarter 2025 Financial Results and Provides Business Update More
• Denali Therapeutics: Third Quarter 2025 Financial Results and Business Highlights More
• Exclusive VC Funding Data from BYTE51, with Special Big4Bio Pricing More
• Guardant Health: Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) More
• JPM Week Conference Readiness Packages (Big4Bio Subscriber Discount) More
• LSN: Hot Investor Mandates (Updated 11/04) More
• Maze Therapeutics: Third Quarter 2025 Financial Results and Recent Highlights More
• More on BillionToOne IPO Becoming $5 Billion Explosion As Bay Area Medical Test Maker’s Stock Soars in Debut More*
• More on Braveheart Bio Bagging $185M for Drug That Could Rival a Bristol Myers Squibb Cardio Med More*
• Nurix Targets $250 Million Stock Sale to Back Pivotal Study of Leukemia Drug More*
• Pliant Therapeutics: Corporate Update and Reports Third Quarter 2025 Financial Results More
• Rani Therapeutics: Third Quarter 2025 Financial Results; Provides Corporate Update More
• Rezolute: First Quarter Fiscal 2026 Financial Results and Provides Business Update More
• Seer: Third Quarter 2025 Financial Results More
• Spotlight: Essential Financial Moves to Help You Survive the Biotech Winter More
• Structure Therapeutics: Third Quarter 2025 Financial Results and Recent Highlights More
• ‘We Jumped All Over It’: How Drug Maker Evommune Took Advantage of the Federal Shutdown To Nail a $150 Million IPO More* More*
  

Media/Misc Coverage

• BioPharmGuy News: Weight Lost, AI Letters, Post Doctor, Correlation Lawsuit, Mr. Peanut Butter More 
  
• Subscribe to LifeSci Startup for Updates on US Startups More
• The Big4Bio Podcast: Every Moment Matters: Navigating the Complexities of Drug Discovery Podcast

Companies

Career Center

• Feature: The Rise of Fractional Talent in Life Sciences: What to Expect in 2026 More
• ICYMI: CEO’s Perspective: Big Moves Come with Big Responsibility More
• ICYMI: CEO’s Perspective: The High Cost of Job Hopping More
• ICYMI: Elevating Executive Presence: A Blueprint for Life Sciences and Biotech Leaders More
• ICYMI: The Power of Peer Learning - Why Even Top Biotech Leaders Need Mentorship More
• ICYMI: What’s Next in Precision Medicine: Leadership Challenges and Opportunities More
• OrbiMed-Backed Biotech Quickly Changes CEOs; Adaptimmune Co-Founder to Lead Evaxion More*
• SJU: Path to Commercialization - Jennifer Rafferty (Field Reimbursement Manager) From Regeneron Podcast

• BIO-Europe 2025 Nov 11-12
• Copay, Reimbursement and Access Congress (Save 10% with VIP code: 25B4B10) Nov 18-20
• Pharma/Biotech Gross-To-Net Summit (Save 10% with VIP code: 25B4B10) Nov 18-20
• Patient Support Services Congress (Save 10% with VIP code: 25B4B10) Nov 20-21
• Compounding Pharmacy Compliance (Save 10% with VIP code: 25B4B10) Dec 9-10
• Trade and Channel Strategies (Save 10% with VIP code: 25B4B10) Dec 9-11
  
• Advancing Drug Development Forum Dec 11

SF Bay Sponsors